Long non-coding RNA expression profiles predict clinical phenotypes in glioma

Neurobiology of Disease

Volumn 48, Issue 1, 2012, Pages 1-8

  Zhang, Xiaoqin ^a   Sun, Stella ^a   Pu, Jenny Kan Suen ^a   Tsang, Anderson Chun On ^a   Lee, Derek ^a   Man, Venus On Ying ^a   Lui, Wai Man ^a   Wong, Stanley Thian Sze ^a   Leung, Gilberto Ka Kit ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Astrocytoma; Glioma; LncRNA profiling; Malignancy; Oligodendroglioma

Indexed keywords

UNTRANSLATED RNA;

ARTICLE; ASTROCYTOMA; CANCER GRADING; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE OVEREXPRESSION; GLIOMA; HISTOLOGY; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIOMA; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; UPREGULATION;

ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; GENE EXPRESSION PROFILING; HUMANS; OLIGODENDROGLIOMA; PHENOTYPE; RNA, LONG UNTRANSLATED;

EID: 84863708888     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.06.004     Document Type: Article

References (84)

1. Axlund S.D., Lambert J.R., Nordeen S.K. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes. Mol Cancer Res. 2010, 8:1643-1655.
2. Barsyte-Lovejoy D., et al. The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. Cancer Res. 2006, 66:5330-5337.
3. Beier D., et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007, 67:4010-4015.
4. Beltran M., et al. A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial-mesenchymal transition. Genes Dev. 2008, 22:756-769.
5. Benetatos L., Vartholomatos G., Hatzimichael E. MEG3 imprinted gene contribution in tumorigenesis. Int J Cancer. 2011, 129:773-779.
6. Bolstad B.M., et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003, 19:185-193.
7. Bonnefont J., et al. Primate-specific RFPL1 gene controls cell-cycle progression through cyclin B1/Cdc2 degradation. Cell Death Differ. 2011, 18:293-303.
8. Bono H., et al. Systematic expression profiling of the mouse transcriptome using RIKEN cDNA microarrays. Genome Res. 2003, 13:1318-1323.
9. Davis M.E., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010, 464:1067-1070.
10. Dinger M.E., et al. Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation. Genome Res. 2008, 18:1433-1445.
11. Eisen M.B., et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998, 95:14863-14868.
12. Farazi T.A., et al. miRNAs in human cancer. J Pathol. 2011, 223:102-115.
13. Freije W.A., et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004, 64:6503-6510.
14. French P.J., et al. Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res. 2005, 65:11335-11344.
15. Fuller G.N. The WHO Classification of Tumours of the Central Nervous System, 4th edition. Arch Pathol Lab Med. 2008, 132:906.
16. Gibb E.A., Brown C.J., Lam W.L. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011, 10:38.
17. Gibb E.A., et al. Human cancer long non-coding RNA transcriptomes. PLoS One. 2011, 6:e25915.
18. Giordano T.J., et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res. 2009, 15:668-676.
19. Gravendeel L.A., et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 2009, 69:9065-9072.
20. Gupta R.A., et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010, 464:1071-1076.
21. Guttman M., et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009, 458:223-227.
22. Guttman M., et al. Ab initio reconstruction of cell type-specific transcriptomes in mouse reveals the conserved multi-exonic structure of lincRNAs. Nat Biotechnol. 2010, 28:503-510.
23. Hessels D., et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003, 44:8-15. discussion 15-6.
24. Hibi K., et al. Loss of H19 imprinting in esophageal cancer. Cancer Res. 1996, 56:480-482.
25. Hou J., et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One. 2010, 5:e10312.
26. Huang H., et al. Gene expression profiling and subgroup identification of oligodendrogliomas. Oncogene. 2004, 23:6012-6022.
27. Huang K.C., et al. Relationship of XIST expression and responses of ovarian cancer to chemotherapy. Mol Cancer Ther. 2002, 1:769-776.
28. Huarte M., Rinn J.L. Large non-coding RNAs: missing links in cancer? Hum Mol Genet. 2010, 19:R152-R161.
29. Irizarry R.A., et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003, 31:e15.
30. Irizarry R.A., et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003, 4:249-264.
31. Ji P., et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003, 22:8031-8041.
32. Johnson R. Long non-coding RNAs in Huntington's disease neurodegeneration. Neurobiol Dis. 2011, 46:245-254.
33. Kaikkonen M.U., Lam M.T., Glass C.K. Non-coding RNAs as regulators of gene expression and epigenetics. Cardiovasc Res. 2011, 90:430-440.
34. Kamal A.H.M., et al. The impact of gene selection on imbalanced microarray expression data. Bioinformatics and Computational Biology, Proceedings. 2009, 5462:259-269.
35. Khalil A.M., et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A. 2009, 106:11667-11672.
36. Korneev S.A., et al. Novel noncoding antisense RNA transcribed from human anti-NOS2A locus is differentially regulated during neuronal differentiation of embryonic stem cells. RNA. 2008, 14:2030-2037.
37. Li A., et al. Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res. 2009, 69:2091-2099.
38. Lin M., et al. RNA-Seq of human neurons derived from iPS cells reveals candidate long non-coding RNAs involved in neurogenesis and neuropsychiatric disorders. PLoS One. 2011, 6:e23356.
39. Lin R., et al. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene. 2007, 26:851-858.
40. Louis D.N. Molecular pathology of malignant gliomas. Annu Rev Pathol. 2006, 1:97-117.
41. Maher E.A., et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res. 2006, 66:11502-11513.
42. Mariner P.D., et al. Human Alu RNA is a modular transacting repressor of mRNA transcription during heat shock. Mol Cell. 2008, 29:499-509.
43. McIlroy M., et al. Interaction of developmental transcription factor HOXC11 with steroid receptor coactivator SRC-1 mediates resistance to endocrine therapy in breast cancer [corrected]. Cancer Res. 2010, 70:1585-1594.
44. Mercer T.R., et al. Specific expression of long noncoding RNAs in the mouse brain. Proc Natl Acad Sci U S A. 2008, 105:716-721.
45. Mercer T.R., Dinger M.E., Mattick J.S. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009, 10:155-159.
46. Mercer T.R., et al. Long noncoding RNAs in neuronal-glial fate specification and oligodendrocyte lineage maturation. BMC Neurosci. 2010, 11:14.
47. Michelhaugh S.K., et al. Mining Affymetrix microarray data for long non-coding RNAs: altered expression in the nucleus accumbens of heroin abusers. J Neurochem. 2011, 116:459-466.
48. Michiels S., Koscielny S., Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet. 2005, 365:488-492.
49. Miller G.J., et al. Aberrant HOXC expression accompanies the malignant phenotype in human prostate. Cancer Res. 2003, 63:5879-5888.
50. Mills K.I., et al. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood. 2009, 114:1063-1072.
51. Mischel P.S., Cloughesy T.F., Nelson S.F. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci. 2004, 5:782-792.
52. Panzitt K., et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology. 2007, 132:330-342.
53. Parsons D.W., et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008, 321:1807-1812.
54. Petalidis L.P., et al. Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data. Mol Cancer Ther. 2008, 7:1013-1024.
55. Ponting C.P., Belgard T.G. Transcribed dark matter: meaning or myth? Hum Mol Genet. 2010, 19:R162-R168.
56. Popko B., et al. Molecular markers that identify human astrocytomas and oligodendrogliomas. J Neuropathol Exp Neurol. 2002, 61:329-338.
57. Prensner J.R., et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol. 2011, 29:742-749.
58. Qureshi I.A., Mattick J.S., Mehler M.F. Long non-coding RNAs in nervous system function and disease. Brain Res. 2010, 1338:20-35.
59. Rao S.A., Santosh V., Somasundaram K. Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol. 2010, 23:1404-1417.
60. Raychaudhuri S., Stuart J.M., Altman R.B. Principal components analysis to summarize microarray experiments: application to sporulation time series. Pac Symp Biocomput. 2000, 455-466.
61. Rickman D.S., et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res. 2001, 61:6885-6891.
62. Rinn J.L., et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007, 129:1311-1323.
63. Saeed A.I., et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003, 34:374-378.
64. Sasaki Y.T., et al. MENepsilon/beta noncoding RNAs are essential for structural integrity of nuclear paraspeckles. Proc Natl Acad Sci U S A. 2009, 106:2525-2530.
65. Sircoulomb F., et al. Genome profiling of ERBB2-amplified breast cancers. BMC Cancer. 2010, 10:539.
66. Sturn A., Quackenbush J., Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics. 2002, 18:207-208.
67. Sun L., et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell. 2006, 9:287-300.
68. Sunwoo H., et al. MEN epsilon/beta nuclear-retained non-coding RNAs are up-regulated upon muscle differentiation and are essential components of paraspeckles. Genome Res. 2009, 19:347-359.
69. Tahira A.C., et al. Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer. Mol Cancer. 2011, 10:141.
70. Tinzl M., et al. DD3PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer. Eur Urol. 2004, 46:182-186. discussion 187.
71. Tischfield M.A., et al. Homozygous HOXA1 mutations disrupt human brainstem, inner ear, cardiovascular and cognitive development. Nat Genet. 2005, 37:1035-1037.
72. Tsai M.C., et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010, 329:689-693.
73. Tusher V.G., Tibshirani R., Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001, 98:5116-5121.
74. van den Bent M.J., et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol. 2003, 21:2525-2528.
75. van den Boom J., et al. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol. 2003, 163:1033-1043.
76. Venter J.C., et al. The sequence of the human genome. Science. 2001, 291:1304-1351.
77. Wapinski O., Chang H.Y. Long noncoding RNAs and human disease. Trends Cell Biol. 2011, 21:354-361.
78. Yang F., et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology. 2011, 54:1679-1689.
79. Yu W., et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature. 2008, 451:202-206.
80. Yusenko M.V., et al. High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. BMC Cancer. 2009, 9:152.
81. Zhang X., et al. A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab. 2003, 88:5119-5126.
82. Zhang X., et al. A myelopoiesis-associated regulatory intergenic noncoding RNA transcript within the human HOXA cluster. Blood. 2009, 113:2526-2534.
83. Zhang X., et al. Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions. Endocrinology. 2010, 151:939-947.
84. Zhou Y., et al. Activation of p53 by MEG3 non-coding RNA. J Biol Chem. 2007, 282:24731-24742.